| |
|
|
|
Xtalks, online
2023 -7-11
This webinar aims to shed light on three challenging aspects of clinical trials in oncology:
The need for innovative study design for novel therapies,
Patient access and diversity, and
Navigating the ever-changing regulatory landscape.
These topics have become increasingly important as the continued development of precision medicines has led to smaller study populations associated with higher uncertainty on the evidence-base for approval and reimbursement decision-making, while at the same time broad patient access and the external validity of the data need to be ensured. This force-field warrants clever thinking about study design and making adequate use of the evolving regulatory environment.
Protocol design for new and novel therapies:
Developing robust and efficient protocols is crucial for successfully evaluating the safety and efficacy of emerging treatments. Speakers will discuss innovative methodologies, adaptive trial designs and data-driven approaches that optimize trial outcomes while ensuring patient safety. The audience will gain insights into the key considerations for designing oncology trials that account for the unique characteristics of oncology therapies, including personalized medicine, immunotherapies and targeted treatments. Case studies will highlight the impact of optimized protocols on trial efficiency, patient recruitment and overall trial success.
Patient access and diversity:
NODATA
Register for this webinar on innovation in oncology trials to gain valuable insights optimizing trial design, into overcoming barriers and adhering to the evolving regulatory landscape. Ultimately, this knowledge will contribute to equitable access to innovative treatments, improved trial efficiency and enhanced patient outcomes.
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Robert Rachford, Vice President, Biostatistics and Programming, ProPharma Kimberly Futch, Director, Clinical Operations Strategy, ProPharma Shelby Stillwagon, Sr Director, Decentralized Clinical Trials, ProPharma Paula van Hennik, Clinical Group Head, Regulatory Sciences, ProPharma
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2023 -7-11
|
|
|
|
|
|
|
|
Registration:
|
|
Free registration
|
|
|
E-mail:
|
|
ajuurinen@xtalks.com
|
|
|
|
|
|
|
|
|